No Data Yet
Merck is strategically expanding its drug pipeline to mitigate the anticipated revenue loss from its blockbuster drug Keytruda's 2028 patent expiration. The market is focused on the execution risk and the commercial success of new assets needed to replace the multi-billion dollar revenue stream.